You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 6,531,128

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,531,128

Title:	Methods for treating glaucoma
Abstract:	This invention provides a method for treating a subject with glaucoma by administrating a composition containing an agent or molecule which antagonize, inhibits, inactivates, reduce, suppresses, antagonizes, and/or limits the release, synthesis, or production from cells of TNF-.alpha. thereby treating the subject with glaucoma.
Inventor(s):	Wax; Martin B. (Wildwood, MO), Tezel; Gulgun (St. Louis, MO)
Assignee:	Pharmacia Corporation (St. Louis, MO)
Application Number:	09/500,023
Patent Claims:	1. A method for treating a subject with glaucoma comprising the steps of administrating a compound or a composition containing an agent or molecule, which antagonizes, inhibits, inactivates, reduce suppresses, and/or limits the release, synthesis, or production of TNF-.alpha., from cells in the retina, thereby treating the subject with glaucoma. 2. The method of claim 1, wherein the molecule is a recombinant TNF-.alpha. soluble receptor. 3. The method of claim 2, wherein the molecule is etanercept. 4. The method of claim 1, wherein the molecule is an anti-TNF-.alpha. antibody. 5. The method of claim 1, wherein said composition further comprises a diluent and suitable carrier. 6. The method of claim 1, wherein the compound or composition is administered ocularly, parenterally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, intravascularly,or subcutaneously, intraperitonealy, by topical drops or ointment, periocular injection, systemically by intravenous injection or orally, intracamerally into the anterior chamber or vitreous, via a depot attached to the intraocular lens implant inserted during surgery, or via a depot placed in the eye sutured in the anterior chamber or vitreous.

Details for Patent 6,531,128

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2039-02-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2039-02-26
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004	⤷ Try a Trial	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.